Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
41 hedge funds and large institutions have $180M invested in Kaleido Biosciences, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
11% more funds holding
Funds holding: 37 → 41 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
34% less capital invested
Capital invested by funds: $273M → $180M (-$92.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.96M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$518K |
| 3 |
BII
Bainco International Investors
Boston,
Massachusetts
|
+$384K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$377K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$353K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$683K |
| 2 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$525K |
| 3 |
Millennium Management
New York
|
-$63.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$56K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$27.8K |
KLDO Hedge Fund Activity: Q3 2019 in Review
41 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q3 2019, worth a combined $180M — down 34% from $273M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new KLDO positions and 2 closed out — a net gain of 5 holders — while 15 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.96M. The largest seller was Palo Alto Investors, cutting an estimated $683K.
- 41 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q3 2019, up from 37 in Q2 2019.
- Funds reported $180M of Kaleido Biosciences, Inc. Common Stock stock for Q3 2019, down 34% quarter-over-quarter.
- 7 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q3 2019 and 2 closed out, a net change of +5 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q3 2019 was Vanguard Group, an estimated $1.96M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q3 2019 was Palo Alto Investors, an estimated $683K sold.
Based on aggregated 13F filings for Q3 2019.